{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:59:06Z","timestamp":1778857146540,"version":"3.51.4"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmech.2023.115928","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T15:54:21Z","timestamp":1699026861000},"page":"115928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Unlocking the synthetic approaches and clinical application of approved small-molecule drugs for gastrointestinal cancer treatment: A comprehensive exploration"],"prefix":"10.1016","volume":"262","author":[{"given":"Xiao-Jing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piet","family":"Herdewijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Gang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115928_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2023.115928_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ejca.2007.12.015","article-title":"Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s","volume":"44","author":"Karim-Kos","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2023.115928_bib3","first-page":"69","article-title":"Global cancer statistics, CA Cancer","volume":"61","author":"Jemal","year":"2011","journal-title":"J. Clin."},{"key":"10.1016\/j.ejmech.2023.115928_bib4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115928_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1021\/np200906s","article-title":"Natural products as sources of new drugs over the 30 years from 1981 to 2010","volume":"75","author":"Newman","year":"2012","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2023.115928_bib6","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2023.115928_bib7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.coph.2009.08.003","article-title":"The role of chemokines in intestinal inflammation and cancer","volume":"9","author":"Wang","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115928_bib8","first-page":"10","article-title":"The statins as anticancer agents","volume":"9","author":"Chan","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115928_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jcpt.12759","article-title":"Repurposing old drugs in oncology: opportunities with clinical and regulatory challenges ahead","volume":"44","author":"Shah","year":"2019","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115928_bib10","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00210-022-02263-x","article-title":"Drug repurposing-an emerging strategy in cancer therapeutics","volume":"395","author":"Turabi","year":"2022","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115928_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0749-2081(16)30035-3","article-title":"Overview of paclitaxel (TAXOL)","volume":"9","author":"Martin","year":"1993","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.ejmech.2023.115928_bib12","series-title":"Archived from the Original on September 14","article-title":"The American society of health-system pharmacists","year":"2017"},{"key":"10.1016\/j.ejmech.2023.115928_bib13","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/annonc\/mdl104","article-title":"Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer","volume":"17","author":"Green","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib14","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/sj.onc.1207374","article-title":"The spindle checkpoint, aneuploidy, and cancer","volume":"23","author":"Bharadwaj","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2023.115928_bib15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1083\/jcb.200805072","article-title":"Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied","volume":"182","author":"Brito","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115928_bib16","series-title":"Process for the Preparation of Taxol and 10-deacetyltaxol","author":"Colin","year":"1989"},{"key":"10.1016\/j.ejmech.2023.115928_bib17","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (taxol)","volume":"332","author":"Rowinsky","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115928_bib18","doi-asserted-by":"crossref","first-page":"e2168","DOI":"10.7717\/peerj.2168","article-title":"The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells","volume":"4","author":"Attia","year":"2016","journal-title":"PeerJ"},{"key":"10.1016\/j.ejmech.2023.115928_bib19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jpba.2016.05.041","article-title":"Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats","volume":"128","author":"Li","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2023.115928_bib20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(94)90754-4","article-title":"The taxoids: paclitaxel and docetaxel","volume":"344","author":"Gelmon","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115928_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cjoc.201201142","article-title":"An efficient semi\u2010synthetic method to construct docetaxel via sterically crowded linear side chain esterification","volume":"31","author":"Shen","year":"2013","journal-title":"Chin. J. Chem."},{"key":"10.1016\/j.ejmech.2023.115928_bib22","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib23","first-page":"3171","article-title":"Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrative nucleoside transporter 1","volume":"31","author":"Wang","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2023.115928_bib24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/jam.2005.18.198","article-title":"Safety of pulmonary administration of gemcitabine in rats","volume":"18","author":"Gagnadoux","year":"2005","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.ejmech.2023.115928_bib25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00003495-199754030-00009","article-title":"Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer","volume":"54","author":"Noble","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115928_bib26","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1021\/jo00246a002","article-title":"Synthesis of 2-deoxy-2, 2-difluoro-D-ribose and 2-deoxy-2, 2'-difluoro-D-ribofuranosyl nucleosides","volume":"53","author":"Hertel","year":"1988","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2023.115928_bib27","series-title":"Colorectal Cancer: Multimodality Management","first-page":"525","article-title":"Oxaliplatin in the treatment of colorectal cancer","author":"Jacobson","year":"2002"},{"key":"10.1016\/j.ejmech.2023.115928_bib28","first-page":"4","article-title":"Oxaliplatin: mechanism of action and antineoplastic activity","volume":"25","author":"Raymond","year":"1998","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib29","first-page":"93","article-title":"Literature review and practical aspects on the management of oxaliplatin-associated toxicity","volume":"11","author":"Hoff","year":"2012","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.ejmech.2023.115928_bib30","series-title":"Method for Preparing Oxaliplatin","author":"Weizhong","year":"2015"},{"key":"10.1016\/j.ejmech.2023.115928_bib31","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO.2000.18.6.1337","article-title":"Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study","volume":"18","author":"Van Cutsem","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib32","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2023.115928_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","article-title":"Capecitabine: a review","volume":"27","author":"Walko","year":"2005","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115928_bib34","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0968-0896(00)00087-0","article-title":"The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine","volume":"8","author":"Shimma","year":"2000","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115928_bib35","series-title":"N-oxycarbonyl-substituted 5'-Deoxy-5-Fluorocytidines and Pharmaceutical Preparation","author":"Motohiro","year":"1995"},{"key":"10.1016\/j.ejmech.2023.115928_bib36","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1595\/147106708X324845","article-title":"Novel lipophilic platinum (II) compounds of salicylate derivatives","volume":"52","author":"Liu","year":"2008","journal-title":"Platin. Met. Rev."},{"key":"10.1016\/j.ejmech.2023.115928_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ica.2023.121388","article-title":"An overview of recent advancements in anticancer Pt (IV) prodrugs: new smart drug combinations, activation and delivery strategies","volume":"548","author":"Marotta","year":"2023","journal-title":"Inorg. Chim. Acta."},{"key":"10.1016\/j.ejmech.2023.115928_bib38","doi-asserted-by":"crossref","first-page":"8113","DOI":"10.1039\/c0dt00292e","article-title":"The status of platinum anticancer drugs in the clinic and in clinical trials","volume":"39","author":"Wheate","year":"2010","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2023.115928_bib39","series-title":"Novel Synthetic Method of Antitumor Drug Heptyl Platinum","author":"Qingkun","year":"2014"},{"key":"10.1016\/j.ejmech.2023.115928_bib40","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115928_bib41","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1158\/1078-0432.CCR-06-2667","article-title":"Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants","volume":"13","author":"Guida","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115928_bib42","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1182\/blood.V97.8.2440","article-title":"ARG tyrosine kinase activity is inhibited by STI571","volume":"97","author":"Okuda","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115928_bib43","article-title":"Imatinib: a breakthrough of targeted therapy in cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother. Res. Pract."},{"key":"10.1016\/j.ejmech.2023.115928_bib44","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1021\/op300212u","article-title":"A facile total synthesis for large-scale production of imatinib base","volume":"16","author":"Kompella","year":"2012","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2023.115928_bib45","first-page":"27","article-title":"Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC), Target","volume":"8","author":"Kobayashi","year":"2013","journal-title":"Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib46","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.7314\/APJCP.2012.13.10.5177","article-title":"Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis","volume":"13","author":"Qi","year":"2012","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.ejmech.2023.115928_bib47","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115928_bib48","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1158\/1535-7163.MCT-08-0354","article-title":"Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer","volume":"7","author":"Ali","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115928_bib49","series-title":"Quinazoline Derivatives","author":"C","year":"1996"},{"key":"10.1016\/j.ejmech.2023.115928_bib50","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/tcrm.2007.3.2.341","article-title":"Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)","volume":"3","author":"Le Tourneau","year":"2007","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.ejmech.2023.115928_bib51","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/jm0204183","volume":"46","author":"Sun","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115928_bib52","first-page":"333","article-title":"Pancreatic neuroendocrine tumors: signal pathways and targeted therapies","volume":"13","author":"Peng","year":"2013","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.ejmech.2023.115928_bib53","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115928_bib54","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1021\/jo034304q","article-title":"Early amidation approach to 3-[(4-amido)pyrrol-2-yl]-2-indolinones","volume":"68","author":"Manley","year":"2003","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2023.115928_bib55","series-title":"Process for the Preparation of N-[2-Diethylamino)ethyl]-5-[(5-Fluoro-1,2-Dihydro-2-Oxo-3h-Indol-3-Ylidene)methyl]-2,4-Dimethyl-1h-Pyrrole-3-Carboxamide","author":"Christ","year":"2010"},{"key":"10.1016\/j.ejmech.2023.115928_bib56","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2023.115928_bib57","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/1756283X15580743","article-title":"Management of regorafenib-related toxicities: a review","volume":"8","author":"Krishnamoorthy","year":"2015","journal-title":"Therap. Adv. Gastroenterol."},{"key":"10.1016\/j.ejmech.2023.115928_bib58","series-title":"Pharmaceutical Compositions of Acid Methyl Amide 4 [4 - [3-(4 Chloro-3 it Trifluoromethylphenyl) - Ureido Linkage] it 3 it Fluorophenoxy) - Pyridine-2-Carboxylic","author":"Riedl","year":"2005"},{"key":"10.1016\/j.ejmech.2023.115928_bib59","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.canlet.2016.01.014","article-title":"Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer","volume":"372","author":"Roviello","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2023.115928_bib60","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","article-title":"Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial","volume":"31","author":"Li","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib61","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib62","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1358\/dot.2015.51.4.2320599","article-title":"Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors","volume":"51","author":"Scott","year":"2015","journal-title":"Drugs Today"},{"key":"10.1016\/j.ejmech.2023.115928_bib63","series-title":"Pharmaceutical Composition for Treating Hyperplasia Diseases","author":"Yuan","year":"2010"},{"key":"10.1016\/j.ejmech.2023.115928_bib64","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1021\/jm8001263","article-title":"4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1","volume":"51","author":"Menear","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115928_bib65","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115928_bib66","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115928_bib67","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bjc.2014.418","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","author":"Golan","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2023.115928_bib68","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1158\/1535-7163.MCT-11-0278","article-title":"Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft","volume":"10","author":"Senra","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115928_bib69","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00259-014-2712-z","article-title":"Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer","volume":"41","author":"Lee","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2023.115928_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102218","article-title":"Metastatic colorectal cancer: advances in the folate-fluoropyrimidine chemotherapy backbone","volume":"98","author":"Glimelius","year":"2021","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2023.115928_bib71","series-title":"Uracyl-derivatives and Antitumor Effect Potentiator and Antitumor Agent Containing the Same","author":"Tetsuji","year":"2001"},{"key":"10.1016\/j.ejmech.2023.115928_bib72","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40265-018-0963-x","article-title":"Encorafenib and binimetinib: first global approvals","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115928_bib73","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/CCO.0000000000000426","article-title":"Development of encorafenib for BRAF-mutated advanced melanoma","volume":"30","author":"Koelblinger","year":"2018","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib74","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib75","series-title":"Compounds and Compositions as Protein Kinase Inhibitors","author":"Huang","year":"2011"},{"key":"10.1016\/j.ejmech.2023.115928_bib76","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.4161\/15384047.2014.964087","article-title":"Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy","volume":"15","author":"Sun","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2023.115928_bib77","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/17512433.2019.1630272","article-title":"The clinical application of fruquintinib on colorectal cancer","volume":"12","author":"Chen","year":"2019","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115928_bib78","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib79","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S1470-2045(18)30140-2","volume":"19","author":"Xu","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib80","series-title":"Quinazoline Derivatives and Medical Application Thereof","author":"Weiguo","year":"2011"},{"key":"10.1016\/j.ejmech.2023.115928_bib81","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1021\/acs.molpharmaceut.9b00274","article-title":"Avapritinib: a selective inhibitor of KIT and PDGFR\u03b1 that reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cell lines","volume":"16","author":"Wu","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2023.115928_bib82","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib83","series-title":"Compositions Useful for Treating Disorders Related to Kit","author":"Hodous","year":"2017"},{"key":"10.1016\/j.ejmech.2023.115928_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2023.115928_bib85","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2023.115928_bib86","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib87","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/08164622.2022.2086792","article-title":"Transient pemigatinib-induced subretinal fluid accumulation and serous retinal detachment","volume":"106","author":"Bloom","year":"2023","journal-title":"Clin. Exp. Optom."},{"key":"10.1016\/j.ejmech.2023.115928_bib88","series-title":"Substituted Tricyclic Compounds as FGFR Inhibitors","author":"Liangxing","year":"2020"},{"key":"10.1016\/j.ejmech.2023.115928_bib89","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s40265-020-01348-2","article-title":"Ripretinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115928_bib90","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","article-title":"Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2023.115928_bib91","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib92","series-title":"Synthesis Method of Revatinib","author":"Lipeng","year":"2023"},{"key":"10.1016\/j.ejmech.2023.115928_bib93","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","article-title":"Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2(+)-advanced solid tumors, with an expansion cohort in HER2(+) metastatic breast cancer (MBC)","volume":"23","author":"Moulder","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115928_bib94","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115928_bib95","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.clbc.2021.06.001","article-title":"Evaluation of tucatinib in HER2-positive breast cancer patients with brain metastases: a United States-based cost-effectiveness analysis","volume":"22","author":"Dong","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ejmech.2023.115928_bib96","series-title":"Preparation Method of Tucatinib","author":"Hai","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115928_bib97","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \"prime time\" in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115928_bib98","first-page":"1","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor for the treatment of FGFR-aberrant tumors","author":"Javle","year":"2023","journal-title":"Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib99","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2020.38.15_suppl.108","article-title":"FOENIX-CCA2: a phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements","volume":"38","author":"Goyal","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib100","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/JCO.2022.40.16_suppl.4009","article-title":"Updated results of the FOENIX-CCA2 trial: efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions\/rearrangements","volume":"40","author":"Goyal","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib101","series-title":"3,5-Disubstituted Alkynylbenzene Compound and Salt Thereof","author":"Takeshi","year":"2015"},{"key":"10.1016\/j.ejmech.2023.115928_bib102","doi-asserted-by":"crossref","first-page":"9480","DOI":"10.1021\/acs.jmedchem.5b01346","article-title":"Discovery of a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase (CB-5083)","volume":"58","author":"Zhou","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115928_bib103","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/1535-7163.MCT-14-0219","article-title":"TAS-116, a highly selective inhibitor of heat shock protein 90\u03b1 and \u03b2, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models","volume":"14","author":"Ohkubo","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115928_bib104","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1517\/14712598.2.1.3","article-title":"HSP90 as a new therapeutic target for cancer therapy: the story unfolds","volume":"2","author":"Maloney","year":"2002","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.ejmech.2023.115928_bib105","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10637-022-01285-9","article-title":"An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors","volume":"40","author":"Komatsu","year":"2022","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2023.115928_bib106","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1200\/JCO.2005.00.612","article-title":"Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies","volume":"23","author":"Banerji","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib107","series-title":"Azabicyclo Compound and Salt Thereof","author":"Kitade","year":"2012"},{"key":"10.1016\/j.ejmech.2023.115928_bib108","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115928_bib109","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejmech.2023.115928_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.873240","article-title":"Editorial: gastrointestinal tumor heterogeneity and related anti-cancer strategies","volume":"12","author":"Liao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib111","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.jchromb.2011.05.056","article-title":"Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry","volume":"879","author":"Wang","year":"2011","journal-title":"J. Chromatogr., B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ejmech.2023.115928_bib112","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/dmd.114.061093","article-title":"Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine","volume":"43","author":"Shah","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2023.115928_bib113","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0169-5002(03)00189-2","article-title":"Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)","volume":"41","author":"Cappuzzo","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2023.115928_bib114","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115928_bib115","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.3816\/CLC.2007.s.003","article-title":"Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies","volume":"8","author":"Gandara","year":"2007","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ejmech.2023.115928_bib116","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/annonc\/mdv176","article-title":"Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial","volume":"26","author":"Normanno","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2023.115928_bib117","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.bbrc.2015.08.022","article-title":"Magnetic nanoparticle-based drug delivery for cancer therapy","volume":"468","author":"Tietze","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2023.115928_bib118","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","article-title":"Liquid biopsy: from discovery to clinical application","volume":"11","author":"Alix-Panabi\u00e8res","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2023.115928_bib119","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2013.53.5948","article-title":"What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials","volume":"32","author":"Kotronoulas","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:02:20Z","timestamp":1759330940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423008954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":119,"alternative-id":["S0223523423008954"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115928","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unlocking the synthetic approaches and clinical application of approved small-molecule drugs for gastrointestinal cancer treatment: A comprehensive exploration","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115928"}}